Financial

Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes

Financial by 0 comments

NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2026 Russell indexes reconstitution, effective after the U.S. market close on June 26, 2026. The Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place until the next semi-annual reconstitution, means automatic inclusion in small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Russell indexes are part of FTSE Russell, a leading global index provider. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12.2 trillion in assets are benchmarked against Russell’s U.S. indexes. For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website here. About Orchestra BioMedOrchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates – Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) – are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and a global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn. About FTSE RussellFTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $12.2 trillion in assets are benchmarked against Russell’s U.S. indexes. For over 30 years, leading asset owners, asset managers, ETF providers, and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth, and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit www.ftserussell.com. References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release. Investor Contact:Silas NewcombOrchestra BioMedSnewcomb@orchestrabiomed.com Media Contact:Nina PremuticoOrchestra BioMednpremutico@orchestrabiomed.com

Continue Reading →

Conavi Medical Receives $1.25 Million Milestone Payment Under Ontario Life Sciences Scale-Up Fund

Financial by 0 comments

Company has received $1.75 million in total under the program, including a $1.25 million payment triggered by the Company’s U.S. FDA clearance, to support the commercial launch of its hybrid IVUS-OCT imaging systemTORONTO, June 29, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (“Conavi” or the “Company”) (TSXV: CNVI; OTCQB: CNVIF), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has received a milestone payment of $1.25 million from the Province of Ontario through the Life Sciences Scale-Up Fund (“LSSUF”). The milestone payment was triggered by Conavi’s achievement of U.S. FDA 510(k) clearance for its hybrid imaging system — the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. “We are grateful to the Province of Ontario, the Ministry of Economic Development, Job Creation and Trade, and Minister Vic Fedeli for their continued support of Conavi,” said Tom Looby, Chief Executive Officer of Conavi Medical. “Having received $1.75 million under the program, we are pleased that this milestone payment recognizes our achievement of FDA clearance. This funding supports the commercialization of our hybrid imaging system as we build our presence in the U.S. market following FDA clearance.” As previously announced, Conavi entered into an agreement with the Province of Ontario in October 2025 under the LSSUF program, which provides support to help Ontario-based life sciences companies scale their operations and commercialize innovative technologies. Under the agreement, Conavi is eligible to receive up to $2.5 million in funding based on the achievement of specified milestones. Following receipt of the $1.25 million milestone payment, the Company has now received a total of $1.75 million under the program to date. The Company remains eligible to receive additional funding under the program, subject to the achievement of future milestones. The Company will use the proceeds received under the LSSUF program to support commercialization initiatives, manufacturing scale-up activities and other eligible project costs associated with the launch of its hybrid imaging system. About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration. For more information, visit http://www.conavi.com/. Notice on forward-looking statementsThis press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the commercialization and commercial launch of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging and the ability of Conavi’s hybrid imaging system to meet market needs. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. CONTACT:Chief Financial Officer: Mark Quick, 416-483-0100Investors: Christina Cameron, 416-483-0100 ext.121, IR@conavi.com

Continue Reading →

Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders

Financial by 0 comments

June 24, 2026 | Globe Newswire MINNEAPOLIS, June 24, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, reviews the year-to-date and outlines strategic priorities in a Letter to Shareholders from newly appointed CEO, Mike McCormick.   Dear Valued […]

Continue Reading →

CardioMech Shareholders Appoint Ramin Mousavi as Chairman of the Board

Financial by 0 comments

MINNEAPOLIS, June 24, 2026  — Norway-based CardioMech AS, a medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology in Fridley, MN, today announced the appointment of Ramin Mousavi as Chairman of the Board , effective immediately.   Mousavi, a seasoned medtech executive with leadership experience across cardiovascular, structural heart, […]

Continue Reading →

EchoIQ Strengthens Leadership Team and Clinical Advisory Network to Accelerate Next Phase of Commercial Growth and U.S. FDA Initiatives

Financial by 0 comments

Matthew Dodds appointed Chief Financial Officer, bringing over 30 years of healthcare, medical technology, capital markets, corporate development and investor relations experience Dr. Vinod Thourani appointed Clinical Advisor, adding one of the world’s leading structural heart and valve disease specialists to Echo IQ’s growing network of key opinion leaders SYDNEY, June 24, 2026 (GLOBE NEWSWIRE) — AI and Medical Technology Company Echo IQ Limited (ASX: EIQ) (“Echo IQ” or “the Company”) today announced two key appointments to its executive leadership team and broader clinical advisory network to support the next phase of commercial growth for its EchoSolv platform, expand its presence within the U.S. healthcare market and advance regulatory initiatives with the U.S. FDA. Matthew Dodds has been appointed Chief Financial Officer, effective 24 June 2026, and Dr. Vinod Thourani, internationally recognised as one of the foremost authorities in structural heart disease, heart valve therapies and cardiovascular surgery, has been appointed Clinical Advisor. Management commentary: Chief Executive Officer, Mr. Dustin Haines said: “These appointments significantly strengthen both the commercial and clinical foundations of Echo IQ as we continue executing our growth strategy in the U.S. Matthew brings a rare combination of healthcare operating experience, strategic leadership, capital markets expertise and investor engagement capability. During his more than 30-year career, Matthew has worked across Wall Street, Johnson & Johnson and LivaNova, providing Echo IQ with an executive who understands not only how to build and scale medical technology businesses, but also how to effectively communicate value to high-profile U.S. investors and strategic partners. As we continue expanding our commercial footprint and evaluating strategic opportunities in the U.S. healthcare sector and more broadly, Matthew’s experience will be invaluable. We are excited to welcome Dr. Vinod Thourani as a Clinical Advisor. Vinod is widely regarded as one of the world’s leading experts in structural heart disease and valve therapies, with an exceptional reputation across both the clinical and academic cardiovascular communities. His appointment further strengthens our already impressive network of key opinion leaders and complements the Company’s existing relationships with internationally recognised clinicians, including Dr. Philippe Genereux, reinforcing the growing interest from leading cardiovascular specialists in the role artificial intelligence can play in improving disease detection and patient outcomes. Together, these appointments further position Echo IQ to accelerate commercial adoption, deepen engagement with leading healthcare institutions and continue building a world-class cardiovascular AI platform.” Chief Financial Officer, Mr. Matthew Dodds added: “I am excited to join Echo IQ at an important stage in the Company’s evolution. Echo IQ has built a differentiated platform addressing major unmet needs in cardiovascular care and sits at the intersection of artificial intelligence, clinical workflow and scalable healthcare technology. I look forward to working with Dustin, the Board and the broader team to help build the financial, strategic and commercial infrastructure required for the Company’s next phase of growth.” Bio for Matthew Dodds, Chief Financial Officer Mr. Dodds joins Echo IQ with more than 30 years of experience across healthcare, medical technology, capital markets, corporate development, strategy, investor relations, business development and public company leadership. Most recently, he served as Senior Vice President, Corporate Development & IT at LivaNova PLC, where he was a member of the executive leadership team and held responsibility for corporate development, investor relations, corporate communications, enterprise IT and strategic initiatives. Prior to LivaNova, Mr. Dodds served as Vice President, Strategic Planning for Johnson & Johnson Medical Devices, helping lead strategic planning, business development and investor relations initiatives across one of the world’s largest medical technology businesses. Earlier in his career, Mr. Dodds spent more than two decades on Wall Street as a leading medical technology equity research analyst, including serving as Americas Sector Head of Healthcare Equity Research at Citigroup. During this period, he advised institutional investors on many of the world’s largest healthcare and medical device companies, developing extensive relationships across the global healthcare investment community. Mr. Dodds earned his Bachelor of Science degree in industrial management from Carnegie Mellon University. Bio for Dr. Vinod Thourani Dr. Thourani currently serves as the Bernie Marcus Chairman of the Department of Cardiovascular Surgery at Piedmont Healthcare and the Marcus Heart and Vascular and Valve Center of the Piedmont Heart Institute in Atlanta, Georgia, where he also serves as Surgical Director of the Structural Center of Excellence. Dr. Thourani has held numerous leadership positions across the global cardiovascular community, including Past President of the Heart Valve Society, Past President of the Southern Thoracic Surgical Association and Past President of the South Atlantic Cardiovascular Society. He currently serves on the Board of Directors of the Society of Thoracic Surgeons and as its Treasurer, while also holding leadership positions with the International Society of Minimally Invasive Cardiothoracic Surgery, the American College of Cardiology and multiple international cardiovascular organisations. He has authored more than 620 peer-reviewed publications and serves as Principal Investigator or Steering Committee member across numerous landmark structural heart and valve disease clinical trials. Dr. Thourani is widely regarded as one of the leading clinical voices in the diagnosis and treatment of structural heart disease and valvular disorders globally. Authorised for release by the Board of Directors of Echo IQ Limited. Investor Inquiries: Dustin Haines Jeremy FefferChief Executive OfficerManaging DirectorEcho IQLifeSci Advisorsdustin.haines@echoiq.aiP: 212-915-2568 jfeffer@lifesciadvisors.com   ABOUT ECHO IQEcho IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

Continue Reading →

CroíValve Announces Expansion of Series B Financing with $27 Million Additional Capital to Fund DUO Adapt in an Enlarged TANDEM II Study

Financial by 0 comments

DUBLIN–(BUSINESS WIRE)–CroíValve, a pioneering medical device company focused on the development of a novel transcatheter device for the treatment of tricuspid regurgitation, announced today the closing of $20 million Series B expansion financing, along with $7 million European Innovation Council (EIC) and DTIF grant financing. Bringing the total for Series […]

Continue Reading →

Access Vascular and Medline Enter Multi-Year Agreement to Launch Cobranded Next-Generation Vascular Access Catheters

Financial Radiology by 0 comments

BILLERICA, Mass.–(BUSINESS WIRE)–Access Vascular, Inc. (“AVI”), a medical device company specializing in developing advanced vascular access solutions, and Medline, the largest provider of medical-surgical products and supply chain solutions serving all points of care, today announced a multi-year agreement to accelerate the rollout of AVI’s next-generation catheters, HydroMID® and HydroPICC®, which recently received an anti-thrombogenic indication from the FDA. The initiative bolsters Medlin

Continue Reading →

Kardigan Announces Pricing of Upsized Initial Public Offering

Financial by 0 comments

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.–(BUSINESS WIRE)—- $KARD #Kardigan–Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16 per share. The gross proceeds from the offering are expected to be $400 million, before unde

Continue Reading →

AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions

Financial by 0 comments

HONG KONG & SEOUL, South Korea–(BUSINESS WIRE)–AIRS Medical (“the Company”), a global leader in AI solutions for medical imaging, today announced a strategic growth investment from TA Associates (“TA”), a leading global private equity firm. The investment will help fuel AIRS Medical’s next phase of global expansion, advancement of its AI-powered radiology technology solutions and ongoing product innovation. Founded in 2018, AIRS Medical develops AI-native magnetic resonance imaging (“MRI”) ac

Continue Reading →
1 2 3 4 5 … 490